CN102093278B - 一种多尼培南的中间体的制备工艺 - Google Patents
一种多尼培南的中间体的制备工艺 Download PDFInfo
- Publication number
- CN102093278B CN102093278B CN201110055048A CN201110055048A CN102093278B CN 102093278 B CN102093278 B CN 102093278B CN 201110055048 A CN201110055048 A CN 201110055048A CN 201110055048 A CN201110055048 A CN 201110055048A CN 102093278 B CN102093278 B CN 102093278B
- Authority
- CN
- China
- Prior art keywords
- intermediate compound
- solution
- chloride
- reaction
- reacted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 title abstract 3
- 229960000895 doripenem Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- -1 nitro carbobenzoxy-(Cbz) Chemical class 0.000 claims description 14
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 9
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N 4-hydroxyproline Chemical compound OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- BTXLWRWDYZKCPQ-UHFFFAOYSA-N [nitro(phenyl)methyl] carbonochloridate Chemical compound ClC(=O)OC([N+](=O)[O-])C1=CC=CC=C1 BTXLWRWDYZKCPQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002808 molecular sieve Substances 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 claims description 4
- SDJHDRMYZQFJJO-UHFFFAOYSA-N ethanethioic s-acid;potassium Chemical compound [K].CC(S)=O SDJHDRMYZQFJJO-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 235000015320 potassium carbonate Nutrition 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 claims description 3
- ONVZFCHLOZUXRP-UHFFFAOYSA-N 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC(NC=2C(NC(=O)C=2C=2C=C(Cl)C=CC=2)=O)=C1 ONVZFCHLOZUXRP-UHFFFAOYSA-N 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000086 high toxicity Toxicity 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000009413 insulation Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- WPCQASPMIALUEE-UHFFFAOYSA-N tert-butyl n-sulfamoylcarbamate Chemical compound CC(C)(C)OC(=O)NS(N)(=O)=O WPCQASPMIALUEE-UHFFFAOYSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OTTZHAVKAVGASB-UHFFFAOYSA-N 2-heptene Natural products CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C)OC(N(C[C@]1NC[C@](*)C1)S(N)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@]1NC[C@](*)C1)S(N)(=O)=O)=O 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940072181 other beta-lactam antibacterials in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110055048A CN102093278B (zh) | 2011-03-09 | 2011-03-09 | 一种多尼培南的中间体的制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110055048A CN102093278B (zh) | 2011-03-09 | 2011-03-09 | 一种多尼培南的中间体的制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102093278A CN102093278A (zh) | 2011-06-15 |
CN102093278B true CN102093278B (zh) | 2012-10-03 |
Family
ID=44126567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110055048A Active CN102093278B (zh) | 2011-03-09 | 2011-03-09 | 一种多尼培南的中间体的制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102093278B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617433B (zh) * | 2012-02-21 | 2014-03-12 | 江西富祥药业股份有限公司 | 一种(2s,4r)-1-对硝基苄氧羰基-4-甲磺酰基吡咯烷-2-甲醇的制备方法 |
CN105439931B (zh) * | 2015-11-21 | 2018-06-22 | 河南海利华生物科技发展有限公司 | 一种多尼培南药物中间体多尼培南侧链的纯化方法 |
CN105541691B (zh) * | 2016-02-05 | 2018-03-20 | 沈晓光 | 一种多尼培南中间体的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1896057A (zh) * | 2005-07-15 | 2007-01-17 | 成都地奥九泓制药厂 | 吡咯烷衍生物中间体及其制备方法和用途 |
WO2007031858A2 (en) * | 2005-09-15 | 2007-03-22 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of beta-lactam antibiotic |
CN101007806A (zh) * | 2006-01-27 | 2007-08-01 | 上海医药工业研究院 | 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体 |
-
2011
- 2011-03-09 CN CN201110055048A patent/CN102093278B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1896057A (zh) * | 2005-07-15 | 2007-01-17 | 成都地奥九泓制药厂 | 吡咯烷衍生物中间体及其制备方法和用途 |
WO2007031858A2 (en) * | 2005-09-15 | 2007-03-22 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of beta-lactam antibiotic |
CN101007806A (zh) * | 2006-01-27 | 2007-08-01 | 上海医药工业研究院 | 一种吡咯烷硫基碳青霉烯衍生物的制备方法及其中间体 |
Non-Patent Citations (6)
Title |
---|
Development》.2003,第7卷(第5期),649-654. * |
Yasuyoshi Iso,et al.A Novel lβ-Methylcarbapenem Antibiotic, S-4661 Synthesis and Structure-activity Relationships of 2-(5-Substituted Pyrrolidin-3-ylthio)-lβ-methylcarbapenems.《JOURNAL OF ANTIBIOTICS》.1996,第49卷(第2期),199-209. * |
YasuyoshiIso,etal.ANovellβ-MethylcarbapenemAntibiotic S-4661 Synthesis and Structure-activity Relationships of 2-(5-Substituted Pyrrolidin-3-ylthio)-lβ-methylcarbapenems.《JOURNAL OF ANTIBIOTICS》.1996 |
Yutaka Nishino,et al.Practical Large-Scale Synthesis of the 2-Aminomethylpyrrolidin-4-ylthio-Containing Side Chain of the Novel Carbapenem Antibiotic Doripenem.《Organic Process Research & Development》.2003,第7卷(第5期),649-654. |
Yutaka Nishino,et al.Practical Large-Scale Synthesis of the 2-Aminomethylpyrrolidin-4-ylthio-Containing Side Chain of the Novel Carbapenem Antibiotic Doripenem.《Organic Process Research & * |
廖守主等.Doripenem的合成工艺研究.《中国抗生素杂志》.2008,第33卷(第2期),125-127. * |
Also Published As
Publication number | Publication date |
---|---|
CN102093278A (zh) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1883790A (zh) | 一种回收合成乙酰磺胺酸钾过程中所用催化剂的工艺 | |
CN102093278B (zh) | 一种多尼培南的中间体的制备工艺 | |
WO2011141847A1 (en) | An improved process for the preparation of meropenem | |
CN110563600A (zh) | 一种磷酸奥司他韦的制备方法 | |
CN100460389C (zh) | 吡咯烷衍生物中间体及其制备方法和用途 | |
CN108069998A (zh) | 一种培南类药物中间体的合成方法 | |
CN106279175A (zh) | 一种厄他培南单钠盐的制备方法 | |
KR100295740B1 (ko) | N-치환된-하이드록시고리화알킬아민유도체의제조방법 | |
CN109180752A (zh) | 一种从阿米卡星合成液中回收卡那霉素a的方法 | |
JP2020506160A (ja) | アビバクタムの簡便な調製方法 | |
CN101481346B (zh) | 一种碳青霉烯类抗生素侧链的制备方法 | |
CN103333180B (zh) | 一种阿扑西林的制备方法 | |
CN101376643B (zh) | 一种碳青霉烯类青霉素厄他培南的中间体的制备方法 | |
CN115073458A (zh) | 一种阿维巴坦钠的制备方法 | |
CN111303045A (zh) | 2-乙氧基-4,6-二氟嘧啶的生产工艺 | |
EP3912970A1 (en) | Method for preparing s-(-)-benzoylmercapto-2-methylpropanoic acid compound | |
CN113527277B (zh) | 卢立康唑及其盐酸盐的生产方法 | |
CN102603595A (zh) | (s)-奥拉西坦的制备方法 | |
CN102603594A (zh) | (s)-奥拉西坦的制备方法 | |
CN111960984B (zh) | 一种合成多尼培南侧链中间体的制备方法 | |
KR100781821B1 (ko) | 카르바페넴계 화합물의 제조방법 | |
CN1051908A (zh) | 直接分离巯甲丙脯酸的方法 | |
CN111675641B (zh) | 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法 | |
CN113929684B (zh) | 一种美罗培南中间体及其制备方法 | |
CN111196781B (zh) | 一种改进的制备五氟利多的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation process for intermediate of doripenem Effective date of registration: 20140416 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000275 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150518 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000275 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation process for intermediate of doripenem Effective date of registration: 20150717 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000572 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161108 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000572 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation process for intermediate of doripenem Effective date of registration: 20161207 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2016990001081 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 100101 No. 2 building, No. 19, Beiyuan East Road, 2508, Beijing, Chaoyang District, 25 Patentee after: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Address before: 100101 Beijing Chaoyang District Anli Road, Sunshine Plaza, No. 68 room C1-802 Patentee before: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: Wen Ying Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181107 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2016990001081 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation process for intermediate of doripenem Effective date of registration: 20181212 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2018990001192 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190805 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2018990001192 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of an intermediate of donipenem Effective date of registration: 20200903 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: Beijing Lunarsun Pharmaceutical Co.,Ltd. Registration number: Y2020990001066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CB03 | Change of inventor or designer information |
Inventor after: Cui Dongdong Inventor after: Zhang Xiaobo Inventor after: Qian Fengchang Inventor before: Cui Dongdong Inventor before: Zhang Xiaobo |
|
CB03 | Change of inventor or designer information | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230628 Granted publication date: 20121003 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020990001066 |